Physician profile
Ralph E Gilmore
NPI 1073525911
$2,589.79
in general payments reported to CMS, 2019-2025
15 companies · $321 in 2025
The $321 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $340 · 2020: $195 · 2021: $302 · 2022: $541 · 2023: $428 · 2024: $463 · 2025: $321.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,212.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,211.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $460.21 | 2019-2024 | Total30, Precision 1 |
| Coopervision INC. | $440.81 | 2019-2025 | Myday Contact Lens |
| Sun Pharmaceutical Industries INC. | $349.04 | 2019-2024 | Cequa |
| Bausch & Lomb Americas INC. | $307.85 | 2022-2025 | Infuse, Miebo, Xiidra |
| Johnson & Johnson Vision Care, INC. | $206.29 | 2021-2025 | Acuvue |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $159.77 | 2020-2021 | |
| Oyster Point Pharma, INC. | $153.63 | 2023-2025 | Tyrvaya |
| Allergan, INC. | $131.29 | 2021 | |
| Glaukos Corporation | $124.80 | 2022 | |
| Tarsus Pharmaceuticals, INC. | $110.75 | 2025 | Xdemvy |
| Novartis Pharmaceuticals Corporation | $49.06 | 2020-2022 | |
| Carl Zeiss Meditec Ag | $38.80 | 2020 | |
| Harrow Eye, LLC | $25.19 | 2025 | Vevye |
| Eyevance Pharmaceuticals LLC | $16.78 | 2022 | |
| Ocular Therapeutix, INC. | $15.52 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ralph Gilmore listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.